Update on manufacturing progress for a novel allogeneic fibroblast topical therapy for diabetic foot ulcers and supply implications.
Key Takeaways
- Preclinical data suggest CYWC628 may significantly accelerate wound healing compared to currently available treatments
- FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways
- These forward-looking statements are based on FibroBiologics' management's current expectations